EDAP TMS shares surge 11.01% intraday after reporting record 2025 HIFU revenue, strong Focal One sales, and 2026 guidance.

EDAP TMS surged 11.01% intraday after announcing record 2025 HIFU revenue driven by strong Focal One sales and a 28% year-over-year increase in U.S. procedures. The company also issued 2026 guidance projecting HIFU revenue of $50–54 million, reflecting sustained demand and clinical adoption of its prostate cancer treatment technology. CEO Ryan Rhodes highlighted growing hospital network acceptance and clinical validation as key growth drivers. The results included a 69% year-over-year rise in Focal One system placements, underscoring global market momentum. These positive operational and financial updates aligned with the stock’s sharp intraday rally, signaling investor confidence in the company’s expanding revenue potential and market position.